American Heart Association

medication

VITALITY-HFpEF: Designed to test the hypothesis that vericiguat may improve physical functioning in patients with HFpEF

Contributor: Emily Cendrowski

VITALITY-HFPEF is a trial underway which will evaluate the efficacy of vericiguat in HFpEF patients by using the KCCQ-PLS (Kansas City Cardiomyopathy Questionnaire Physical Limitation Score) as a primary endpoint. The choice of this primary endpoint will make it the first HF trial utilizing a quality of life, patient-reported outcome (PRO) as a primary endpoint. There remains a need for medications which improve mortality and functional status for patients with HFpEF. An ongoing area of research involves the cyclic guanosine monophosphate (cGMP) pathway.

By |October 25th, 2019|clinical trials, Emily Cendrowski, HFpEF, medication, quality of life, sGC activator|0 Comments
Read More

Visual Abstract: Factors Associated with Persistently Low Sacubitril/Valsartan Use

Contributors: Ike Chinyere and Steven Stroud

Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

Study Link: Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

By |January 17th, 2019|Ike Chinyere, sacubitril/valsartan, Steven Stroud, Visual Abstract|0 Comments
Read More

Low Adoption Rates of Sacubitril/Valsartan Use in the US

Contributor: Nick Hawkes

Sacubitril/valsartan reduces morbidity and mortality in patients with HFrEF, so why has the adoption of this therapy in the outpatient setting been so slow?

By |November 14th, 2018|Entresto, HFrEF, Nicholas Hawkes, sacubitril/valsartan|0 Comments
Read More

Oxidative state of cGMP-dependent protein kinase determines the efficacy of sildenafil vs direct guanylate cyclase activators in pressure-overload HF

Contributor: Elise Vo

Precision therapy for HF is on the horizon. Activating cyclic guanosine monophosphate (cGMP)-dependent protein kinase-1α (PKG1α), results in vasodilation and prevents cardiac remodeling — a good thing. There are two ways to activate PKG1a: 1) directly soluble guanylate cyclase (sGC) activators and 2) indirectly by PDE5 inhibition. So, do these two methods of targeting PKG1α work equally well? Nakamura et al used a TAC murine model to demonstrate that the oxidative state of PKG1α determines whether or not sildenafil is efficacious in preventing pathologic remodeling in pressure-overload HF.

By |September 14th, 2018|Elise Vo, protein kinase G-1 alpha, sGC activator, sildenafil|0 Comments
Read More

Slow Adoption and Low Adherence of Sacubitril/Valsartan for HFrEF

Contributor: Nick Hawkes

PARADIGM – HF demonstrated that Sacubitril/Valsartan reduces morbidity and mortality in patients with HFrEF compared to ACE-I/ARB therapy, so why is its adoption in the real world delayed?

Sangaralingham et al. accessed data from OptumLabs Data Warehouse, a large database of de-identified medical and pharmacy claims. Among patients identified based on systolic HF ICD codes, those prescribed sacubitril/valsartan were compared to those who were not. Patient variables included health plan, age, gender, race, region, comorbidities, other prescription medications, and provider specialty. Additionally the costs, out-of-pocket (OOP) and to the health plan, were captured.

By |September 7th, 2018|ACE-I/ARB, Entresto, HFrEF, Nicholas Hawkes, PARADIGM-HF|0 Comments
Read More